Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 3, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 484,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年7月5日，生物技术公司Taysha Gene Therapies，Inc.（纳斯达克：TSHA）宣布，该公司董事会的薪酬委员会于2024年7月3日授予四名新员工共购买公司普通股48.4万股的期权，以作为他们入职Taysha的诱因，这些期权是根据纳斯达克上市规则5635（c）（4）以Taysha Gene Therapies，Inc.2023年诱因计划的形式授予的。
The stock options have an exercise price of $2.15 per share, which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.
这些股票期权的行使价格为每股2.15美元，与授予日Taysha的普通股的收盘价相等。该股票期权的有效期为10年，并将在四年内归属，其中该期权的25%将在归属开始日期的第一周年纪念日上归属，剩余的75%将在此后36个月按照平均月份归属并逐月返还。该股票期权的归属取决于该员工继续为Taysha提供服务直到每次归属日期为止。
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit
关于Taysha Gene Therapies
Taysha Gene Therapies（Nasdaq：TSHA）是一家临床阶段的生物技术公司，致力于推进以脑中枢神经系统的严重单基因病为重点的基于腺相关病毒的基因疗法。其领先的临床计划TSHA-102正在开发用于Rett综合症，这是一种罕见的神经发育性障碍，没有经过批准的改变疾病根源的疾病修饰治疗方法。Taysha的领导团队在基因疗法开发和商业化方面具有丰富的经验。Taysha利用这种经验、其制造工艺以及已经具有临床和商业证明的AAV9衣壳，试图从实验室到床旁快速转化治疗方法。有关更多信息，请访问
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
公司联系人：
Hayleigh Collins
董事，企业传播和投资者关系负责人
Taysha Gene Therapies，Inc。
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
媒体联系人：
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
Source: Taysha Gene Therapies, Inc.
来源：Taysha Gene Therapies，Inc。